奥氮平致代谢紊乱和心血管疾病研究进展
发布时间：2018-10-09 12:11
【摘要】：正抗精神病药物是治疗精神分裂症(schizophrenia,SZ)及其他精神病性障碍的最主要手段,目前临床广泛使用的第二代抗精神病药物(second generation antipsychotics,SGA),尤其是奥氮平,能够引起以肥胖和胰岛素抵抗(insulin resistance,IR)为主的代谢紊乱(metabolic disorder),显著增加2型糖尿病和心血管疾病(cardiovascular disease,CVD)的风险[1-3]。研究发现长期使用奥氮平的患者,代谢紊乱和CVD的发生率是普通人群2~3倍[4],因此近年来,奥氮平致代谢紊乱和CVD的机制备受关注。代谢紊乱是CVD的重要危险因素,而近期研究发现奥氮平所致代谢紊
[Abstract]:Positive antipsychotics are the most important treatment for schizophrenia (schizophrenia,SZ) and other psychotic disorders. At present, the second generation antipsychotic drug (second generation antipsychotics,SGA), especially olanzapine, is widely used in clinical practice. Metabolic disorders such as obesity and insulin resistance (insulin resistance,IR) are associated with (metabolic disorder), significantly increasing the risk of type 2 diabetes and cardiovascular disease (cardiovascular disease,CVD) [1-3]. It has been found that the incidence of metabolic disorder and CVD in patients with olanzapine for a long time is three times higher than that in the general population. Therefore, the mechanism of metabolic disorder and CVD induced by olanzapine has attracted much attention in recent years. Metabolic disorder is an important risk factor for CVD, and recent studies have found that the metabolism of olanzapine is orderly.
【作者单位】： 上海交通大学医学院附属精神卫生中心;Division
【基金】：国家自然科学基金面上项目(编号:81171266,81271481) 上海市重性精神病重点实验室(编号:13dz2260500) 上海市科技创新计划(编号:11140900400)201108
【分类号】：R54;R749
[Abstract]:Positive antipsychotics are the most important treatment for schizophrenia (schizophrenia,SZ) and other psychotic disorders. At present, the second generation antipsychotic drug (second generation antipsychotics,SGA), especially olanzapine, is widely used in clinical practice. Metabolic disorders such as obesity and insulin resistance (insulin resistance,IR) are associated with (metabolic disorder), significantly increasing the risk of type 2 diabetes and cardiovascular disease (cardiovascular disease,CVD) [1-3]. It has been found that the incidence of metabolic disorder and CVD in patients with olanzapine for a long time is three times higher than that in the general population. Therefore, the mechanism of metabolic disorder and CVD induced by olanzapine has attracted much attention in recent years. Metabolic disorder is an important risk factor for CVD, and recent studies have found that the metabolism of olanzapine is orderly.
【作者单位】： 上海交通大学医学院附属精神卫生中心;Division
【基金】：国家自然科学基金面上项目(编号:81171266,81271481) 上海市重性精神病重点实验室(编号:13dz2260500) 上海市科技创新计划(编号:11140900400)201108
【分类号】：R54;R749
【相似文献】
相关期刊论文 前10条
1 张德亮,孟庆玲;奥氮平致严重低血钾1例[J];中国临床药学杂志;2000年05期
2 吴向平,范小琴;超量服奥氮平抢救成功1例[J];上海精神医学;2004年05期
3 ;奥氮平和利培酮不宜用于老年痴呆患者[J];药物不良反应杂志;2004年05期
4 赵黎君;韩耀静;罗烈岚;;奥氮平与利培酮治疗痴呆患者的行为和精神症状的对照研究[J];中国民康医学;2006年05期
5 王德林;孟庆丰;;国产奥氮平对脑器质性精神障碍的疗效分析[J];中国神经免疫学和神经病学杂志;2008年01期
6 何凡;郑毅;;奥氮平治疗难治性Tourette综合征1例[J];临床精神医学杂志;2008年06期
7 毛星;刘洪秋;陈玉辉;;奥氮平与阿立哌唑治疗难治性精神分裂症70例的对照研究[J];中国民康医学;2010年11期
8 毛星;陈玉辉;刘洪秋;;奥氮平治疗难治性精神分裂症45例的疗效分析[J];中国民康医学;2010年13期
9 任季冬;戢彬;蔡旭明;;奥氮平与利培酮治疗老年期精神障碍的对照研究[J];检验医学与临床;2010年09期
10 杨雀屏;张恒;包pせ，
本文编号：2259290
本文链接：https://www.wllwen.com/yixuelunwen/jsb/2259290.html
最近更新
教材专著
